cytotoxic Flashcards
cyclophosphamide - MOA, cell most affected, dose?
alkylating agent of DNA
derivative of nitrogen mustard - FDA + MF
B cells > T cels (best for vasculiditis, bullous disorders, etc)
1-3 mg/kg PO OD (typically dosed at 100-200 mg /day
cyclophosphamide c/i?
hypersensitivity
relative: hemorrhagic cystitis bladder fibrosis bladder cancer other malignancy
s.e of cyclophosphamide?
antimitotic:
GI: N/V/D
GU: hemorrhagic cystitis (5-41%), hematuria, fibrosis, contracture, urgency, dysuria
infectious
heme - anemia, leukopenia, etc
neoplastic - bladder, leukemia, lymphoma, cutaneous SCCs
repro: amenorrhea , azospermia, premature ovarian failure
preggo : contraindicated
cyclophosphamide skin s/e
anagen, reversible
pigmentation of teeth, skin, nails
urticaria, mucosal ulcers, aSJS
cyclophosphamide - way to avoid bladder damage?
mesna - binds to acrolin which is thought to create irritation in the first place
hydrate
surveil
cyclophosphamide monitoring?
Initiate: history and physical, esp LNA and
#####age appropriate Ca screening ###
starting labs: CBCd, basic chem, LFTs, urinalysis
reduce dose or avoid if Q3M)
urinalysis + cytology after cumulative dose >50 g and Q6month thereafter or if ?hemorrhagic cystitis
hydroxyurea - 5 cutaneous s/e
PIGMENT, PHOTOSENSITIZER!!!! (SUN AND RADIATION)
- DM-like eruption
- Hyperpigmentation of skin/nails
- Photosensitivity
- Radiation recall
- nonmelanoma skin Ca
- drug-induced LE
- leg ulcers
- lichenid drug eruptions (similar to cGVHD)
- alopecia (reversible)
hydroxyurea monitoring
Monitoring (same for all cytotox drugs)
- history, physical,drug interactiosn
- baseline labs: CBCd, basic chem, LFTs, Cr, BUN, urinalysis, +- tuberculin testing, pregnancy test (category D)
- ongoing: CBCd, LFTs weekly, urinalysis -> biweekly - > monthly x 3 months, then Q3 months
- repeat with any dose changes
- d/c med If decree Hb decrease by 3 g/dl, WBC< 3.5 or plts <100
- complete physical with skin exams for skin Ca Q6M